Capecitabine monotherapy doesn't improve survival in elderly patients with early-stage breast cancer

Visit www.ecancer.org for more.
At a press conference at SABCS 2014, Prof von Minckwitz (German Breast Group, Neu-Isenburg, Germany) presents negative data out of the phase III ICE trial.
In elderly breast cancer patients with moderate- to high-risk early-stage disease for whom standard chemotherapy is too toxic, the chemotherapy capecitabine, which causes fewer side effects than the standard chemotherapy agents, did not improve outcomes when tested as monotherapy.